rhIGF-I/rhIGFBP-3

Phase 2Small molecule

Takeda

rhIGF-I/rhIGFBP-3 is one of 68 small molecule programs targeting Myotonic Dystrophy Type 1. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myotonic Dystrophy Type 1Active, not recruiting

Retinopathy of PrematurityActive, not recruiting

GrowthActive, not recruiting

Myotonic Dystrophy Type 1Phase 2

Active, not recruiting

Retinopathy of PrematurityPhase 2

Active, not recruiting

GrowthPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

Lovenox

Sanofi

Preclinical

2 3

Aricept

Eisai

Preclinical

1 4

Lenvima

Eisai

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

rhIGF-I/rhIGFBP-3

Takeda

Phase 2

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Somavaratan

EGRIFTA WR

2 10

Glucophage

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth1 trial

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

Completed·IInsmed Incorporated·Phase 2/3·NCT00368173

Retinopathy of Prematurity1 trial

IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity

Completed· Takeda logo

Takeda·Phase 2·NCT01096784·121 enrolled

Myotonic Dystrophy Type 11 trial

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

Completed·IInsmed Incorporated·Phase 2·NCT00577577·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for rhIGF-I/rhIGFBP-3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rhIGF-I/rhIGFBP-3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rhIGF-I/rhIGFBP-3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

rhIGF-I/rhIGFBP-3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth1 trial

Retinopathy of Prematurity1 trial

Myotonic Dystrophy Type 11 trial

References

Drug Info

Quick Facts

Related News